Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway-Reference-Cited by-同舟云学术

Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway

Published:2009-05 Issue:7 Volume:45 Page:1265-1273
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Meira Debora Dummer,Nóbrega Isabel,de Almeida Vitor Hugo,Mororó Jânio S.,Cardoso Alexander M.,Silva Ricardo L.A.,Albano Rodolpho M.,Ferreira Carlos Gil

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer;Newby;Clin Cancer Res,1997

2. Epidermal growth factor receptor dependence in human tumors: more than just expression?;Arteaga;Oncologist,2002

3. Untangling the ErbB signalling network;Yarden;Nat Rev Mol Cell Biol,2001

4. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab;Li;Cancer Cell,2005

5. Mechanisms of resistance to erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells;Arnoletti;J Gastrointest Surg,2004

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Welding PROxAb Shuttles: A Modular Approach for Generating Bispecific Antibodies via Site-Specific Protein–Protein Conjugation;Bioconjugate Chemistry;2024-05-29

2. Welding PROxAb Shuttles: A modular approach for generating bispecific antibodies via site-specific protein-protein conjugation;2024-03-15

3. How does understanding epigenetics help circumvent HER-2 antibody resistance?;Overcoming Cancers Resistant to HER-2 Antibodies;2024

4. A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response;OncoImmunology;2023-04-24

5. Targeted cancer therapy: The future of drug combinations;Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies;2023